The Oncology department is proud to offer a newly released chemotherapy drug for canine lymphoma. Tanovea-CA1 has conditional approval from the FDA for treatment of lymphoma in dogs. The active ingredient in Tanovea is rabacfosadine, a substance that works by killing rapidly dividing cancer cells. Tanovea is administered as a 30 minute intravenous infusion every 3 weeks for up to 5 doses. Conditional approval by the FDA requires a reasonable expectation of effectiveness and this drug is generally well tolerated. Discuss with your oncologist to determine if your dog is a good candidate for this new therapy.

Learn more >